Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK Cell Therapy for Hepatocellular Carcinoma
NCT06044506Phase 1Recruiting
- Sponsor
- Dr. Cipto Mangunkusumo Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous natural killer cells in hepatocellular carcinoma (HCC), sponsored by Dr. Cipto Mangunkusumo Hospital. Primary endpoint: Optimal treatment dosage at 6 months. Started Aug 2022; status: recruiting.
02
Drugs
autologous natural killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06044506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044506.